COMPARISON OF EFFICACY AND SAFETY OF DEXMEDETOMIDINE AND PROPOFOL INFUSION FOR SEDATION DURING FIBREOPTIC NASOTRACHEAL INTUBATION
Nidhi Garg1, Tejinderpal Kaur Grewal2, Deepak Garg3

HOW TO CITE THIS ARTICLE:

ABSTRACT: Fibreoptic intubation is a valuable modality for airway management. This study aimed to compare the efficacy and safety of dexmedetomidine and propofol infusion for sedation during fibreoptic nasotracheal intubation. Twenty patients of either sex aged between 18 to 60 years belonging to ASA I or ASA II grade were enrolled and randomly allocated into the dexmedetomidine group (1.0 μg/kg infusion over 10 min followed by 0.5 µg/kg/hr. during fibreoptic nasotracheal intubation) (n = 10) and the propofol group (100µg/kg/min body weight over 10 min followed by 50µg/kg/min during fibreoptic nasotracheal intubation) (n = 10). Intubating conditions and patient tolerance as graded by a scoring system were evaluated as primary outcomes. Intubation was successful in all patients. Satisfactory intubating conditions were found in both groups (10/10 in each group). In the evaluation of efficacy it was found that dexmedetomidine group had better patient tolerability according to 5 point fibreoptic intubation comfort score (3.0±1.05 and 1.8±1.03 in propofol and dexmedetomidine group respectively [p<0.05]). In the evaluation of safety it was found that in dexmedetomidine group better Spo2 is maintained during intubation (p<0.05), there was significant decrease in diastolic blood pressure in propofol group at the end of infusion (p<0.05) and there was significant decrease in pulse rate in dexmedetomidine group than propofol group at the end of infusion (p<0.05). Both drugs infusion are effective and safe to be used as sedative agent during fibreoptic nasotracheal intubation with same incidence of amnesia but better patient tolerance and Spo2 maintenance with dexmedetomidine.

KEYWORDS: Fibreoptic nasotracheal intubation, dexmedetomidine, propofol, infusion.

INTRODUCTION: Endotracheal intubation is the gold standard for maintenance of airway patency and gas flow, providing an open airway in anesthesiology. Tracheal intubation is the placement of a flexible plastic tube into the trachea to maintain a patent airway for ventilation. Endotracheal intubation can be done via mouth (orotracheal intubation) or via nose (nasotracheal intubation). Nasotracheal intubation can be done blindly, with the help of laryngoscope (with or without Magill’s forceps) or fibreoptic nasotracheal intubation. Fibreoptic intubation can be performed awake under sedation with or without topical anesthesia or with muscle relaxant (suxamethonioum, Vecuronium, rocuronium, atracurium). For sedation, drugs that may be used are fentanyl/opioids, midazolam, propofol, dexmedetomidine, remifentanil. Propofol is a short-acting, intravenously administered hypnotic agent. Its uses include the induction and maintenance of general anesthesia, sedation for mechanically ventilated patients and procedural sedation. The currently available preparation is 1%propofol, 10% soyabean oil, 1.2%purified egg phospholipid (emulsifier), with 2.25% of glycerol as a tonicity-adjusting agent and sodium hydroxide to adjust the pH. It acts through potentiation of GABA-A receptor activity, thereby slowing the calcium-closing time and also acting as a sodium
channel blocker. Hypotension, oxyhemoglobin desaturation, apnea, and airway obstruction can occur, especially following a rapid bolus of Propofol. Dexmedetomidine is a highly selective, potent α2-agonist, with a short duration of action. It contains an imidazole ring. This new sedative has the ability to sedate and provide analgesia while maintaining patient arousability and respiratory function. The α2A receptors are located in the locus ceruleus and are responsible for the sedation, anxiolysis and sympatholysis mediated by G-protein inhibition of L-type calcium channels in the post-synaptic receptors. It has biphasic cardiovascular response as initially result in a transient increase of the blood pressure due to peripheral post-synaptic α2B stimulation with vasoconstriction\(^1\). Then there would be hypotension and bradycardia due to stimulation of pre-synaptic α2A with decreased norepinephrine\(^2\). This hypotension can be managed with atropine, ephedrine and volume infusion\(^3\). The respiratory depression has been reported to be much less than with other sedatives\(^4\). Atipamezole, α-2 antagonist, is an effective antagonist for reversing psychomotor impairment following dexmedetomidine sedation\(^5\).

**MATERIAL AND METHODS:** The study was conducted in Government Medical College, Patiala. Total 20 Patients aged between 18-60 years and of ASA Grade I and II scheduled to undergo elective surgery were selected and randomly divided in two groups of 10 each.

**Exclusion criteria:**
- History of severe bradycardia and any type of A-V block in E.C.G
- Heart failure
- Liver cirrhosis
- Thrombocytopenia and Coagulopathy
- History of hypertension/diabetes mellitus/bronchial asthma/previous nasal surgery/nasal trauma/nasal polyp

**METHOD:** All patients received Inj.Glycopyrrolate (0.2mg) i/m 30 min before the elective surgery. Group I patients received dexmedetomidine infusion 1µg/kg body weight over 10 min followed by 0.5µg/kg/hr. during fibreoptic nasotracheal intubation. The infusion was prepared by adding 2ml (200µg) of dexmedetomidine to 48ml of 0.9% saline solution making overall solution of 50ml. Group II patients received propofol infusion 100µg/kg/min body weight over 10 min followed by 50µg/kg/min during fibreoptic nasotracheal intubation. The infusion was prepared by diluting adequate amount of propofol according to body weight in 0.9% saline solution making overall solution of 50ml. Xylometazoline nasal drops were applied to both nostrils. Lidocaine jelly was applied to fiberscope and nostril. The nostril with least resistance was selected for nasal intubation. Nasopharyngeal airway (28 or 30 no.) introduced into nostril selected as dilator and for lubrication. Fibreoptic nasotracheal intubation was done in both groups of patients. After intubation, Isoflurane 1%, Vec (0.06-0.08mg/kg) was administered.

Clinically patients were monitored and following observation were recorded during the course of intubation:
**Intraoperatively:**

1) Baseline, patient vitals (BP, Heart rate, SpO₂) were documented. During infusion, patient vitals (BP, Heart rate, SpO₂) were documented at 0, 5, 10 mins. During intubation, patient vitals (BP, heart rate, SpO₂) were documented at 0, 3, 6 min.

2) Intubation scores –
   a) Vocal cord movements (open=1, moving=2, closing=3, closed=4)
   b) Coughing (none=1, slight=2, moderate=3, severe=4).
   c) Limb movement (none=1, slight=2, moderate=3, severe=4).

3) Intubation time (time taken from inserting the fibreoptic scope to confirmation of nasotracheal intubation).

4) Patient tolerance assessed by:
   a) 5 point fibreoptic intubation comfort score (no reaction=1, slight grimacing=2, heavy grimacing=3, verbal objection=4, defensive movement of head or hands=5).
   b) 3 point score immediately after nasotracheal intubation (cooperative=1, restless/minimal resistance=2, severe resistance=3).

5) Any complication or any drug used during procedure is noted.

**ETHICS:** While performing this study on human subjects, the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975 that was revised in 2000.

**DISCUSSION AND RESULTS:** During infusion in propofol group, mean baseline pulse rate was 78.4±5.15 which at 5 min of infusion was 70.4±3.86 and at 10 min was 65.8±2.74. In comparison dexmedetomidine group had mean baseline pulse rate of 77.4±5.34, at 5 min was 69±5.44 and at 10 min was 60.8±1.69. There was significant difference between two groups with decreased pulse rate in dexmedetomidine group at end of infusion. During intubation in propofol group, mean baseline pulse rate was 65.8±2.74 which at 3 min was 64.8±2.7 and at 6 min was 63±2.54. In comparison dexmedetomidine group had mean baseline pulse rate of 64.4±4.3 which at 3 mins and 6 mins was 63.6±3.86 and 65.6±4.40 respectively. There was no significant difference between two groups during intubation. Tsai et al⁶ in their study comparing dexmedetomidine and propofol target controlled infusion for sedation during fibreoptic nasotracheal intubation also found that heart rate was decreased significantly in dexmedetomidine group at the end of drug infusion. Similarly Venn R M⁷ while comparing dexmedetomidine and propofol sedation in ICU postoperative patients also found that heart rate was decreased significantly in dexmedetomidine group. In another study by Yusuke et al⁸ while comparing sedation of dexmedetomidine and propofol in healthy volunteers also found that heart rate decreased significantly in dexmedetomidine group. Bloor BC et al⁹ in their study of 37 healthy volunteers evaluated the hemodynamic effects of dexmedetomidine infusion also found that heart rate was decreased during dexmedetomidine infusion.

The Systolic blood pressure in our study shows no significant difference among two groups both during infusion and intubation. During infusion in propofol group, mean baseline systolic blood pressure, mean SBP at 5 mins and 10 mins were 126.8±4.24, 118.4±3.98 and 110.8 with S.D 5.09 respectively. In dexmedetomidine group during infusion, mean baseline systolic blood pressure, mean SBP at 5 mins and 10 mins were 126.6±3.78, 130.8±4.24 and 118.0±5.89. During intubation in
propofol group, mean baseline systolic blood pressure was 110.8±5.09 which at 3 mins was 108.2±4.66 and at 6 mins was 108.6±4.05. In dexmedetomidine group during intubation, mean baseline systolic blood pressure, mean SBP at 3 mins and 6 mins were 111.4±5.89, 107.8±5.61 and 110.0±6.73 respectively. The diastolic blood pressure in our study however shows significant difference in two groups, by virtue of fall of DBP in dexmedetomidine group late in the procedure i.e. during intubation. During infusion in propofol group, mean baseline diastolic blood pressure, mean DBP at 5 mins and 10 mins were 81.2±3.79, 74.4±3.46 and 70.4±1.84 respectively.

In dexmedetomidine group during infusion, mean baseline diastolic blood pressure, mean DBP at 5 mins and 10 mins were 79.2±4.83, 79.2±4.13 and 68.4±2.8. During intubation in propofol group, mean baseline diastolic blood pressure was 70.4±1.84 which at 3 mins was 69±4.03 and at 6 mins was 64±3.80. In dexmedetomidine group during intubation, mean baseline diastolic blood pressure, mean DBP at 3 mins and 6 mins were 68.4±2.80, 66.4±4.09 and 67.6±3.73 respectively. Tsai et al6 in their study comparing dexmedetomidine and propofol target controlled infusion for sedation during fibreoptic nasotracheal intubation, found that there was no significant difference of mean blood pressure between two groups. Venn R M7, also in their study comparing dexmedetomidine and propofol sedation in ICU postoperative patients had found no significant difference of systolic blood pressure between two groups.

Hall JE et al10 while evaluating sedation, analgesia, cognition and effect on cardiorespiratory function of dexmedetomidine infusion in 7 healthy young volunteers, didn’t found any significant hemodynamic changes during dexmedetomidine infusion. Knolle E et al11 also found no significant hemodynamic instability while evaluating the target controlled infusion of propofol for fibreoptic intubation in 20 patients scheduled for outpatient oral surgery. Stuart AG et al12 evaluated dexmedetomidine infusion for sedation during fibreoptic intubation on 3 patients and they found that fibreoptic intubation was successful in all patients without any hemodynamic instability. Grant SA et al13 while evaluating the efficacy of dexmedetomidine infusion for sedation during fibreoptic intubation in 3 patients scheduled for cervical spine surgery, didn’t find any significant hemodynamic instability during the procedure. Bergese SD et al14 also found no significant hemodynamic instability while evaluating dexmedetomidine for sedation in difficult awake fibreoptic intubation in 4 patients.

During infusion of drug in propofol group, mean baseline SpO2 was 100±0 which at 5 mins of infusion was 94.4±1.26 and at 10 mins was 93.4±0.97. In comparison dexmedetomidine group had mean SpO2 of 100±0, at 5 min was 94.8±1.93 and at 10 min was 94.2±1.13. There was no significant difference between two groups when comparing SpO2 during infusion. During intubation in propofol group, mean baseline SpO2 was 93.4±0.97 which at 3 min was 95.2±2.35 and at 6 min was 94.2±2.20. In comparison dexmedetomidine group had mean baseline SpO2 of 94.2±1.13 which at 3 mins and 6 mins was 96.6±1.35 and 94.4±0.97 respectively.

There was significant difference between two groups during intubation with better SpO2 maintained in dexmedetomidine group. In our study there was one case of apnea occurring during infusion in propofol group, however patient SpO2 was maintained and patient recovered when fibreoptic bronchoscopy started without any supplemental oxygen. Tsai et al6 in their study also found that hypoxia occurred in 1 patient of propofol group with no significant difference between two groups in terms of SpO2. Hall JE et al7 in their study also concluded that evaluate that during dexmedetomidine infusion SpO2 was well maintained. Grant SA et al13 in their study to evaluate the efficacy of dexmedetomidine infusion for sedation during fibreoptic intubation in 3 patients
scheduled for cervical spine surgery, found that dexmedetomidine did not cause respiratory distress in any patient.

The intubation score when calculated and compared both in components and total showed no significant difference between propofol and dexmedetomidine groups. The mean vocal cord movement score in propofol group was 1.6±0.67 and in dexmedetomidine group was 1.6±0.67. While comparing mean coughing score, it was 2.0±0.67 and 1.7±0.67 in propofol and dexmedetomidine group respectively. The mean limb movement score in propofol group was 1.5±0.53, as compared to 1.8±0.79 in dexmedetomidine group. Comparing mean total intubation score in two groups it was 5.1±1.20 and 5.1±1.29 in propofol and dexmedetomidine group respectively. Tsai et al in their study found that dexmedetomidine group had more favorable intubation score for vocal cord movement than did propofol group but there was no significant difference of intubation score for coughing and limb movement among two groups.

While comparing the patient tolerance in our study, by using 5 point fibreoptic intubation comfort score and 3 points score immediately after fibreoptic intubation, it was found that there was significant difference between two groups especially in intubation comfort score suggesting that dexmedetomidine had better patient tolerability. The mean 5 point fibreoptic intubation comfort score was 3.0±1.05 and 1.8±1.03 in propofol and dexmedetomidine group respectively. The mean 3 point score immediately after fibreoptic intubation in propofol was 1.5±0.53 and in dexmedetomidine group was 1.4±0.52. The total patient tolerance was 4.5±1.17 and 3.2±1.23 in propofol and dexmedetomidine group respectively. Tsai et al while comparing dexmedetomidine and propofol target controlled infusion for sedation during fibreoptic nasotracheal intubation also found that dexmedetomidine group had better patient tolerance than propofol group.

The total duration of intubation show no significant difference between two groups. In propofol group, mean total duration of intubation was 5.66±0.27 and in dexmedetomidine group, mean total duration of intubation was 5.58±0.33. Tsai et al also found that there was no significant difference between two groups in intubation time.

In propofol group, atropine was used in 2 patients for bradycardia. In dexmedetomidine group also, atropine was used in 2 patients for bradycardia. However, there was no incidence of severe bradycardia (HR≤40) in both group patients.

In propofol group, there were 10 patients having postoperative amnesia of fibrescopy and in dexmedetomidine group, there were 8 patients having postoperative amnesia of fibrescopy. Tsai et al also concluded that recall was higher in dexmedetomidine group compared to propofol group.

CONCLUSION: All the above mentioned facts suggest that both dexmedetomidine and propofol infusion provide satisfactory intubating conditions. Both drugs infusion are effective and safe to be used as sedative agent during fibreoptic nasotracheal intubation. Dexmedetomidine offers better patient tolerance during fibreoptic bronchoscopy and intubation with incidence of amnesia same in both groups.

REFERENCES:
During infusion (in minutes) | During intubation (in minutes)
--- | ---
Pulse rate (in bpm) | Propofol | 78.4±5.15 | 70.4±3.86 | 65.8±2.74 | 65.8±2.74 | 64.8±2.7 | 63±2.54
| Dexmedetomidine | 77.4±5.34 | 69±5.44 | 60.8±1.69 | 64.4±4.3 | 63.6±3.86 | 65.6±4.40
Systolic blood pressure (in mm of Hg) | Propofol | 126.8±4.24 | 118.4±3.98 | 110.8±5.09 | 110.8±5.09 | 108.2±4.66 | 108.6±4.05
| Dexmedetomidine | 126.6±3.78 | 130.8±4.24 | 118±5.89 | 111.4±5.89 | 107.8±5.61 | 110±6.73
Diastolic blood pressure (in mm of Hg) | Propofol | 81.2±3.79 | 74.4±3.46 | 70.4±1.84 | 70.4±1.84 | 69±4.03 | 64±3.80
| Dexmedetomidine | 79.2±4.83 | 79.2±4.13 | 68.4±2.8 | 68.4±2.80 | 66.4±4.09 | 67.6±3.73
Spo2 | Propofol | 100±0 | 94.4±1.26 | 93.4±0.97 | 93.4±0.97 | 95.2±2.35 | 94.2±2.20
| Dexmedetomidine | 100±0 | 94.8±1.93 | 94.2±1.13 | 94.2±1.13 | 96.6±1.35 | 99.4±0.97
Fig. 3: Intubation score

AUTHORS:
1. Nidhi Garg
2. Tejinderpal Kaur Grewal
3. Deepak Garg

PARTICULARS OF CONTRIBUTORS:
1. Senior Resident, Department of Anaesthesiology, Sri Guru Ramdas Institute of Medical Sciences and Research, Amritsar, Punjab
2. Associate Professor, Department of Anaesthesiology, Government Medical College, Patiala, Punjab.
3. Senior Resident, Department of Medicine, Sri Guru Ramdas Institute of Medical Sciences and Research, Amritsar, Punjab

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:
Dr. Nidhi Garg,
H. No. 1843, St No. – 8G,
Dasmesh Nagar, Moga – 142001.
E-mail: deepaksir1985@yahoo.in

Date of Submission: 07/02/2014.
Date of Peer Review: 08/02/2014.
Date of Acceptance: 14/02/2014.
Date of Publishing: 25/02/2014.